Build A Drug's Value in Early

Build a Drug's Value in Early

Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.